Tectonic Therapeutic, Inc.

TECX Healthcare Biotechnology

EPS
−10.3%
Free cash flow
−46.7%
Total debt
−94.0%

Quarter to June 2026, against a year earlier

20.62 1.20 +6.18%
Market cap
$379.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
26.63 12.65 0.76 7.62 10.27 16.09 13.96 12.26 2.40 6.03
Net Debt/EBITDA
3.08 2.50 0.65 0.75 1.49 2.18 2.50 2.76 0.33 1.16
Debt/Equity
0.00 0.00 (0.01) 0.20 0.09 0.00 0.00 0.00 0.00 0.00
ROE
(37.82%) (206.56%) 924.30% (86.50%) (56.22%) (54.37%) (47.35%) (98.14%) 135.19% 35.86%
ROA
(35.83%) (60.30%) (59.75%) (68.81%) (50.15%) (50.75%) (43.69%) (69.19%) (301.61%) (80.00%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(29.79%) (42.20%) 622.25% (118.00%) (64.78%) (47.19%) (39.36%) (39.82%) (464.61%) (110.79%)
Average Days of Receivables
— — — 0.00 0.00 0.00 0.00 0.00 — —
Free Cash Flow per Share
(3.29) (6.98) (32.28) (2.23) (2.34) (2.76) (2.52) (2.94) (7.50) (1.63)
Book value per Share
13.72 16.58 (66.69) 1.72 3.95 7.02 6.78 9.09 (10.35) (2.25)
Free Cash Flow
(60.22) (59.24) (40.96) (97.47) (100.49) (99.98) (69.25) (39.48) (16.76) (3.31)
Other line items

Show all line items

Columns are period end dates